AdvaMedDx held a Capitol Hill briefing on the life-saving role of diagnostics and devices to ensure that the U.S. blood supply is safe.
For patients needing transfusions, the U.S. blood supply has never been safer. Thanks to advanced diagnostic testing, innovative devices and other blood safety interventions, it's now rare that someone would ever receive Hepatitis or HIV-infected blood. Health care providers and industry want to apply this same low tolerance for infectious disease risk in blood to another area of transfusions: post-transfusion adverse reaction. This is especially critical for patients that require more frequent transfusions, such as those with Sickle Cell Disease, thalassemia and some patients with cancer. These chronic patients can become highly sensitized to blood transfusions, making it difficult to find the right match. While they can be matched for the two major types of blood groups, there are over a dozen less common blood groups that can also be problematic for them.
Today there are new molecular diagnostic tests that make it possible to quickly and cost-effectively perform extended matching for donors and patients. For patients, this means the possibility of faster access to highly matched blood and a better chance of avoiding adverse transfusion reactions.
To view the videos from the Hill visiting, please click here.
Featured speakers included:
- Dr. Sukanta Banerjee, Senior Director of R&D, BioArray Solutions (an Immucor Company)
- Dr. Arthur Bracey, Pathologist, Gulf Coast Pathology, Blood Banking and Transfusion Medicine
- Dr. Louis Katz, Chief Medical Officer, America’s Blood Centers
- Joann Moulds PhD, MT(ASCP)SBB, Scientific Director, Grifols Immunohematology Center